World shares have retreated after President Trump issued a new set of import duties that will apply to dozens of countries as ...

Stocks capped a choppy day of trading on Wall Street with more losses Thursday after an early Big Tech rally faded and a ...

Asian shares are lower after choppy trading on Wall Street that saw more losses as investors assess President Donald Trump's ...

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q2 CY2025, but sales were flat year on year at $12.27 ...

By Michael Erman (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on ...

Bristol-Myers Squibb P/E Ratio Analysis in Relation to Industry Peers The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company ...

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.